Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK-1701TC

NCT03509220 is registered in ClinicalTrials.gov with Pharmbio Korea Co., Ltd. as lead sponsor.

NCT NCT03509220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03509220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK-1701TC
Lead sponsor
Pharmbio Korea Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 11, 2018
Completion date
October 31, 2018
Enrollment
235 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colonic diseases, digestive system disease, gastrointestinal disease, intestinal disease